HALO
Halozyme Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
RSI Oversold
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HALO
Halozyme Therapeutics, Inc.
A biopharmaceutical company that develops recombinant human enzymes and novel oncology therapies for the tumor microenvironment
12390 El Camino Real, San Diego, California, 92130
--
Halozyme Therapeutics, Inc., is a biopharmaceutical company founded in 1998. In November 2007, the company was reorganized and registered in Delaware (previously registered in Nevada). The company is committed to the development and commercialization of innovative products. The company studies extracellular matrix, extracellular regions, including cell migration, signaling and survival. Over the years, the company has developed unique scientific expertise that allows it to pursue treatments that focus on environmental development.
Earnings Call
Q1/2025
Estimate EPS0.94
Actual EPS1.11
Estimate Revenue230.18M
Actual Revenue265.00M
Halozyme's Q1 2025: Contradictions Unveiled in Patent Litigation, ENHANZE Business, and Partnership Confidence
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.23
Actual EPS1.54
Estimate Revenue285.92M
Actual Revenue326.00M
Halozyme's Q2 2025: Unpacking Contradictions in Patent Litigation, ENHANZE Impact, and Regulatory Challenges
Aug 06,2025 05:51
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS1.59
Actual EPS1.72
Estimate Revenue339.10M
Actual Revenue354.00M
Halozyme's Q3 2025 Earnings Call: Contradictions Emerge on Deal Activity, IP Litigation, ENHANZE Compatibility, Leverage Strategy, and 2026 Revenue Growth
Nov 03,2025 06:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
HALO has released its 2025 Q3 earnings. EPS was reported at 1.72, versus the expected 1.59, beating expectations. The chart below visualizes how HALO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HALO has released its 2025 Q3 earnings report, with revenue of 354.26M, reflecting a YoY change of 22.12%, and net profit of 175.22M, showing a YoY change of 27.89%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
